Teva Pharmaceutical Industries Ltd (ADR)  

(Public, NYSE:TEVA)   Watch this stock  
Find more results for TEVA
50.82
-0.65 (-1.26%)
Real-time:   10:04AM EDT
NYSE real-time data - Disclaimer
Currency in USD
Range 50.76 - 51.15
52 week 48.01 - 66.55
Open 51.11
Vol / Avg. 387,822.00/5.69M
Mkt cap 51.22B
P/E 33.93
Div/yield 0.34/2.68
EPS 1.50
Shares 1.01B
Beta 0.78
Inst. own 59%
Nov 15, 2016
Q3 2016 Teva Pharmaceutical Industries Ltd Earnings Call - 8:00AM EST - Add to calendar
Nov 15, 2016
Q3 2016 Teva Pharmaceutical Industries Ltd Earnings Release - 7:00AM EST - Add to calendar
Sep 9, 2016
Teva Pharmaceutical Industries Ltd to Host Generic Medicines Business Overview - Webcast
Sep 7, 2016
Teva Pharmaceutical Industries Ltd at Wells Fargo Securities Healthcare Conference
Aug 4, 2016
Q2 2016 Teva Pharmaceutical Industries Ltd Earnings Call
Aug 4, 2016
Q2 2016 Teva Pharmaceutical Industries Ltd Earnings Release
Jul 13, 2016
Teva Pharmaceutical Industries Ltd to Provide Preliminary Outlook for 2016-2019
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '16) 2015
Net profit margin 4.51% 8.74%
Operating margin 7.17% 13.85%
EBITD margin - 30.66%
Return on average assets 1.61% 3.41%
Return on average equity 2.49% 6.32%
Employees 42,888 -
CDP Score - 96 B

Address

5 Basel St., P.O. Box 3190
PETAH TIKVA, 49131
Israel
+972-3-9267267 (Phone)
+972-3-9234050 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Transcripts - SeekingAlpha

Description

Teva Pharmaceutical Industries Limited is a global pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. It has a global portfolio of approximately 1,000 molecules. Its central nervous system (CNS) portfolio includes Copaxone for the treatment of multiple sclerosis, Azilect for the treatment of the symptoms of Parkinson's disease and Nuvigil for the treatment of sleep disorders, as well as several therapies for the treatment of pain care. Its main respiratory medicines include ProAir hydrofluoroalkane, QVAR and Duoresp Spiromax. Its oncology portfolio includes Treanda, Trisenox, Granix Synribo in the United States and Lonquex, Tevagrastim/Ratiograstim, Myocet, Trisenox and Eporatio outside the United States. Its women's health portfolio includes ParaGard, Plan B One-Step OTC/Rx (levonorgestrel) and Zoely.

Officers and directors

Yitzhak Peterburg Chairman of the Board
Age: 65
Bio & Compensation  - Reuters
Erez Vigodman President, Chief Executive Officer, Director
Age: 56
Bio & Compensation  - Reuters
Eyal Desheh Group Executive Vice President, Chief Financial Officer
Age: 63
Bio & Compensation  - Reuters
Carlo De Notaristefani President and Chief Executive Officer, Global Operations
Age: 58
Bio & Compensation  - Reuters
Robert Koremans President, Chief Executive Officer - Global Specialty Medicines
Age: 54
Bio & Compensation  - Reuters
Sigurdur Oli Olafsson President and Chief Executive Officer - Global Generic Medicines Group
Age: 47
Bio & Compensation  - Reuters
Richard S. Egosi Group Executive Vice President, Chief Legal Officer
Age: 53
Bio & Compensation  - Reuters
Iris Beck-Codner Group Executive Vice President - Corporate Marketing Excellence and Communication
Age: 50
Bio & Compensation  - Reuters
Mark Sabag Group Executive Vice President, Human Resources
Age: 45
Bio & Compensation  - Reuters
Timothy R. Wright Executive Vice President, Business Development, Strategy and Commercial Innovation
Age: 58
Bio & Compensation  - Reuters